These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27111064)

  • 1. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry.
    Harrold LR; Reed GW; Karki C; Magner R; Shewade A; John A; Kremer JM; Greenberg JD
    Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1888-1893. PubMed ID: 27111064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
    Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
    Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
    Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
    Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
    Yun H; Xie F; Beyl RN; Chen L; Lewis JD; Saag KG; Curtis JR
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1526-1534. PubMed ID: 27813327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
    Melville AR; Md Yusof MY; Fitton J; Garcia-Montoya L; Bailey L; Dass S; Emery P; Buch MH; Saleem B
    Rheumatology (Oxford); 2021 Aug; 60(8):3679-3688. PubMed ID: 33432358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.
    Park DJ; Choi SJ; Shin K; Kim HA; Park YB; Kang SW; Kwok SK; Kim SK; Nam EJ; Sung YK; Lee J; Lee CH; Jeon CH; Lee SS
    Clin Rheumatol; 2017 May; 36(5):1013-1022. PubMed ID: 28243760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL; Arkema EV; Glintborg B; Mehnert F; Østergaard M; Dreyer L; Nørgaard M; Krogh NS; Askling J; Hetland ML;
    Ann Rheum Dis; 2019 Mar; 78(3):320-327. PubMed ID: 30612115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eficiency of different doses of rituximab in rheumatoid arthritis.
    Mena-Vázquez N; Manrique-Arija S; Ureña-Garnica I; Romero-Barco CM; Jiménez-Núñez FG; Coret V; Irigoyen-Oyarzábal MV; Fernández-Nebro A
    Reumatol Clin; 2016; 12(3):139-45. PubMed ID: 26458761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice.
    Toussirot E; Pertuiset E; Sordet C; Augé B; Wendling D; Pallot-Pradès B; Collet P; Lohse A; Balblanc JC
    Joint Bone Spine; 2010 Mar; 77(2):142-5. PubMed ID: 20171921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study.
    Vassilopoulos D; Delicha EM; Settas L; Andrianakos A; Aslanidis S; Boura P; Katsounaros M; Athanassiou P; Tempos K; Skarantavos G; Antoniadis C; Papazoglou S; Sakkas L; Galanopoulou V; Skopouli F; Boki K; Daoussis D; Vritzali E; Sfikakis PP
    Clin Exp Rheumatol; 2016; 34(5):893-900. PubMed ID: 27383049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis.
    Kawashima H; Kagami SI; Kashiwakuma D; Takahashi K; Yokota M; Furuta S; Iwamoto I
    Rheumatol Int; 2017 Mar; 37(3):369-376. PubMed ID: 27999943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
    Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
    Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
    Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
    Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Patarata E; Subesinghe S; Hyrich KL; Galloway JB
    Rheumatology (Oxford); 2018 Jun; 57(6):997-1001. PubMed ID: 29529307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.
    Henry J; Gottenberg JE; Rouanet S; Pavy S; Sellam J; Tubach F; Belkhir R; Mariette X; Seror R;
    Rheumatology (Oxford); 2018 Mar; 57(3):538-547. PubMed ID: 29267905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
    Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
    Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
    Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.